Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HPV type 45 L1 protein is a structural viral component responsible for forming highly stable virus-like particles that are both necessary for infectious particle assembly and serve as potent antigens in preventive vaccines. Its ability to self-organize without additional factors makes it ideal for recombinant production platforms used globally to prevent cervical cancer associated with high-risk HPVs like type 45.
Vaccine-induced neutralizing antibodies targeting conformational epitopes on assembled L1 capsids, preventing viral entry and infection
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 45 major capsid protein L1 (HPV45 L1).